132 related articles for article (PubMed ID: 20587623)
1. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats.
Sugatani J; Sadamitsu S; Kurosawa M; Ikushiro S; Sakaki T; Ikari A; Miwa M
Drug Metab Dispos; 2010 Oct; 38(10):1655-64. PubMed ID: 20587623
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet.
Osabe M; Sugatani J; Fukuyama T; Ikushiro S; Ikari A; Miwa M
Drug Metab Dispos; 2008 Feb; 36(2):294-302. PubMed ID: 17967931
[TBL] [Abstract][Full Text] [Related]
3. Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet: association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4alpha expression.
Sugatani J; Wada T; Osabe M; Yamakawa K; Yoshinari K; Miwa M
Drug Metab Dispos; 2006 Oct; 34(10):1677-87. PubMed ID: 16815962
[TBL] [Abstract][Full Text] [Related]
4. Deteriorating effect of fluvastatin on the cholestatic liver injury induced by bile duct ligation in rats.
Lotková H; Staňková P; Roušar T; Kučera O; Kohoutek L; Mičuda S; Brčáková E; Kolouchová G; Cervinková Z
Gen Physiol Biophys; 2011 Mar; 30(1):66-74. PubMed ID: 21460414
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
Qiang F; Lee BJ; Lee W; Han HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):413-7. PubMed ID: 19428223
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
[TBL] [Abstract][Full Text] [Related]
7. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.
Voûte MT; Winkel TA; Poldermans D
Expert Opin Drug Saf; 2010 Sep; 9(5):793-800. PubMed ID: 20557267
[TBL] [Abstract][Full Text] [Related]
8. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
[TBL] [Abstract][Full Text] [Related]
9. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
10. Updated clinical safety experience with fluvastatin.
Jokubaitis LA
Am J Cardiol; 1994 May; 73(14):18D-24D. PubMed ID: 8198019
[TBL] [Abstract][Full Text] [Related]
11. Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.
Li L; Ma Y; Geng XB; Song YX; Tan Z; Shang XM; Zhao GY; Zhao BQ; Tian MR
Am J Ther; 2016; 23(1):e318-20. PubMed ID: 24451297
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
[TBL] [Abstract][Full Text] [Related]
13. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats.
Lin CH; Hsu KW; Chen CH; Uang YS; Lin CJ
Biochem Pharmacol; 2017 Oct; 142():216-228. PubMed ID: 28636885
[TBL] [Abstract][Full Text] [Related]
14. Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steatosis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet.
Sugatani J; Sadamitsu S; Wada T; Yamazaki Y; Ikari A; Miwa M
Nutr Metab (Lond); 2012 Mar; 9(1):23. PubMed ID: 22452877
[TBL] [Abstract][Full Text] [Related]
15. Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.
Sakamoto K; Mikami H; Kimura J
Br J Pharmacol; 2008 Aug; 154(7):1482-90. PubMed ID: 18500364
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.
Appel-Dingemanse S; Smith T; Merz M
J Clin Pharmacol; 2002 Mar; 42(3):312-8. PubMed ID: 11865968
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin, rhabdomyolysis, and myotoxicity.
Murinson BB; Maragakis NJ; Jacobson TA
Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
[No Abstract] [Full Text] [Related]
18. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
19. The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.
Eng H; Scialis RJ; Rotter CJ; Lin J; Lazzaro S; Varma MV; Di L; Feng B; West M; Kalgutkar AS
Drug Metab Dispos; 2016 May; 44(5):692-9. PubMed ID: 26888941
[TBL] [Abstract][Full Text] [Related]
20. The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects.
Xu HR; Chen WL; Chu NN; Li XN; Zhu JR
J Biomed Biotechnol; 2012; 2012():386230. PubMed ID: 22811596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
